Coordinated Cancer Germline Antigen Promoter and Global DNA Hypomethylation in Ovarian Cancer: Association with the BORIS/CTCF Expression Ratio and Advanced Stage

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2011 Feb 8

PMID 21296871

Citations 51

Authors

Anna Woloszynska-Read

Wa Zhang

Jihnhee Yu

Petra A Link

Paulette Mhawech-Fauceglia

Golda Collamat

Stacey N Akers

Kelly R Ostler

Lucy A Godley

Kunle Odunsi

Adam R Karpf

Affiliations

Soon will be listed here.

Abstract

Purpose: Cancer germline (CG) antigens are frequently expressed and hypomethylated in epithelial ovarian cancer (EOC), but the relationship of this phenomenon to global DNA hypomethylation is unknown. In addition, the potential mechanisms leading to DNA hypomethylation, and its clinicopathologic significance in EOC, have not been determined.

Experimental Design: We used quantitative mRNA expression and DNA methylation analyses to determine the relationship between expression and methylation of X-linked (MAGE-A1, NY-ESO-1, XAGE-1) and autosomal (BORIS, SOHLH2) CG genes, global DNA methylation (5mdC levels, LINE-1, Alu, and Sat-α methylation), and clinicopathology, using 75 EOC samples. In addition, we examined the association between these parameters and a number of mechanisms proposed to contribute to DNA hypomethylation in cancer.

Results: CG genes were coordinately expressed in EOC and this was associated with promoter DNA hypomethylation. Hypomethylation of CG promoters was highly correlated and strongly associated with LINE-1 and Alu methylation, moderately with 5mdC levels, and rarely with Sat-α methylation. BORIS and LINE-1 hypomethylation, and BORIS expression, were associated with advanced stage. GADD45A expression, MTHFR genotype, DNMT3B isoform expression, and BORIS mRNA expression did not associate with methylation parameters. In contrast, the BORIS/CTCF expression ratio was associated with DNA hypomethylation, and furthermore correlated with advanced stage and decreased survival.

Conclusions: DNA hypomethylation coordinately affects CG antigen gene promoters and specific repetitive DNA elements in EOC, and correlates with advanced stage disease. The BORIS/CTCF mRNA expression ratio is closely associated with DNA hypomethylation and confers poor prognosis in EOC.

Citing Articles

The potential value of cancer-testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy.

Lin L, Zou X, Nong W, Ge Y, Li F, Luo B Immun Inflamm Dis. 2024; 12(6):e1284.

PMID: 38896069 PMC: 11186301. DOI: 10.1002/iid3.1284.

Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.

Akhtar M, Akhter N, Talat A, Alharbi R, Sindi A, Klufah F Oncotarget. 2023; 14:528-541.

PMID: 37235839 PMC: 10219660. DOI: 10.18632/oncotarget.28442.

Nucleic acid vaccination strategies for ovarian cancer.

Saha C, Bojdo J, Dunne N, Duary R, Buckley N, McCarthy H Front Bioeng Biotechnol. 2022; 10:953887.

PMID: 36420446 PMC: 9677957. DOI: 10.3389/fbioe.2022.953887.

CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.

Salgado-Albarran M, Spath J, Gonzalez-Barrios R, Baumbach J, Soto-Reyes E NPJ Syst Biol Appl. 2022; 8(1):5.

PMID: 35132075 PMC: 8821627. DOI: 10.1038/s41540-022-00214-z.

approach to understand epigenetics of POTEE in ovarian cancer.

Qazi S, Raza K J Integr Bioinform. 2021; 18(4).

PMID: 34788504 PMC: 8709732. DOI: 10.1515/jib-2021-0028.

References

Yang A, Estecio M, Doshi K, Kondo Y, Tajara E, Issa J . A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res. 2004; 32(3):e38. PMC: 373427. DOI: 10.1093/nar/gnh032. View

Barreto G, Schafer A, Marhold J, Stach D, Swaminathan S, Handa V . Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature. 2007; 445(7128):671-5. DOI: 10.1038/nature05515. View

Link P, Gangisetty O, James S, Woloszynska-Read A, Tachibana M, Shinkai Y . Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res. 2009; 7(6):851-62. PMC: 2836864. DOI: 10.1158/1541-7786.MCR-08-0497. View

Pugacheva E, Suzuki T, Pack S, Kosaka-Suzuki N, Yoon J, Vostrov A . The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One. 2010; 5(11):e13872. PMC: 2975627. DOI: 10.1371/journal.pone.0013872. View

Friso S, Choi S, Girelli D, Mason J, Dolnikowski G, Bagley P . A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A. 2002; 99(8):5606-11. PMC: 122817. DOI: 10.1073/pnas.062066299. View

De Smet C, Loriot A . DNA hypomethylation in cancer: epigenetic scars of a neoplastic journey. Epigenetics. 2010; 5(3):206-13. DOI: 10.4161/epi.5.3.11447. View

Bast Jr R, Hennessy B, Mills G . The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9(6):415-28. PMC: 2814299. DOI: 10.1038/nrc2644. View

Klenova E, Morse 3rd H, Ohlsson R, Lobanenkov V . The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol. 2002; 12(5):399-414. DOI: 10.1016/s1044-579x(02)00060-3. View

Cadieux B, Ching T, VandenBerg S, Costello J . Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 2006; 66(17):8469-76. DOI: 10.1158/0008-5472.CAN-06-1547. View

10.

Wolff E, Byun H, Han H, Sharma S, Nichols P, Siegmund K . Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010; 6(4):e1000917. PMC: 2858672. DOI: 10.1371/journal.pgen.1000917. View

11.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman E . Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(31):12837-42. PMC: 1937553. DOI: 10.1073/pnas.0703342104. View

12.

Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S . Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 2007; 3(10):2023-36. PMC: 2041996. DOI: 10.1371/journal.pgen.0030181. View

13.

James S, Link P, Karpf A . Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene. 2006; 25(52):6975-85. DOI: 10.1038/sj.onc.1209678. View

14.

Robertson K . DNA methylation and human disease. Nat Rev Genet. 2005; 6(8):597-610. DOI: 10.1038/nrg1655. View

15.

Gopalakrishnan S, Van Emburgh B, Shan J, Su Z, Fields C, Vieweg J . A novel DNMT3B splice variant expressed in tumor and pluripotent cells modulates genomic DNA methylation patterns and displays altered DNA binding. Mol Cancer Res. 2009; 7(10):1622-34. PMC: 2783805. DOI: 10.1158/1541-7786.MCR-09-0018. View

16.

Hong J, Kang Y, Abdullaev Z, Flanagan P, Pack S, Fischette M . Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res. 2005; 65(17):7763-74. DOI: 10.1158/0008-5472.CAN-05-0823. View

17.

Simpson A, Caballero O, Jungbluth A, Chen Y, Old L . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8):615-25. DOI: 10.1038/nrc1669. View

18.

Rozen S, Skaletsky H . Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 1999; 132:365-86. DOI: 10.1385/1-59259-192-2:365. View

19.

Greenlee R, Murray T, Thun M . Cancer statistics, 2001. CA Cancer J Clin. 2001; 51(1):15-36. DOI: 10.3322/canjclin.51.1.15. View

20.

Filippova G, Lindblom A, Meincke L, Klenova E, Neiman P, Collins S . A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers. Genes Chromosomes Cancer. 1998; 22(1):26-36. View